生物标志物改善心脏手术后再入院或死亡预测的效用
研究在1046例孤立性冠状动脉旁路移植术出院患者中检测ST2、半乳糖凝集素-3、N末端脑钠肽前体、胱抑素C、白细胞介素-6和白细胞介素-10,并在1194例患者中外部验证。推导队列中生物标志物面板联合胸外科医师学会增强临床模型将30天再入院或死亡预测的AUROC从0.66提高至0.74(p<0.0001),但外部验证改善有限,AUROC为0.51(95%CI 0.45-0.56)。
要点
- 推导队列中生物标志物面板联合临床模型使AUROC从0.66升至0.74(p<0.0001)。
- 外部验证中生物标志物面板改善有限,AUROC为0.51(95%CI 0.45-0.56)。
- 30天再入院或死亡率为10.7%(112例)。
核心结论
- 生物标志物在推导队列中显著改善30天再入院或死亡预测,但外部验证表现差。
- 生物标志物预测再入院表现不佳,提示尚有许多其他因素有待探索。
研究设计与样本
- 推导队列纳入8个医疗中心1046例孤立性冠状动脉旁路移植术后出院患者,外部验证纳入5个医疗中心1194例患者。
- 检测ST2、半乳糖凝集素-3、N末端脑钠肽前体、胱抑素C、白细胞介素-6和白细胞介素-10水平。
- 通过Medicare、州全付费索赔和National Death Index确定30天再入院或死亡。
- 使用受试者工作特征曲线下面积(AUROC)统计检验并外部验证临床模型和生物标志物面板。
主要发现
- 112例(10.7%)患者在冠状动脉旁路移植术后30天内再入院或死亡。
- 胸外科医师学会增强临床模型的AUROC为0.66(95%CI 0.61-0.71)。
- 生物标志物面板联合胸外科医师学会增强临床模型的AUROC为0.74(bootstrapped 95%CI 0.69-0.79,p<0.0001)。
- 外部验证显示加入生物标志物面板改善有限,AUROC为0.51(95%CI 0.45-0.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 外部验证中生物标志物面板表现差,AUROC为0.51(95%CI 0.45-0.56)。
- 生物标志物预测再入院表现不佳,提示尚有许多其他因素有待探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital readmission within 30 days is associated with higher risks of complications, death, and increased costs. Accurate statistical models to stratify the risk of 30-day readmission or death after cardiac surgery could help clinical teams focus care on those patients at highest risk. We hypothesized biomarkers could improve prediction for readmission or mortality. METHODS: Levels of ST2, galectin-3, N-terminal pro-brain natriuretic peptide, cystatin C, interleukin-6, and interleukin-10 were measured in samples from 1,046 patients discharged after isolated coronary artery bypass graft surgery from eight medical centers, with external validation in 1,194 patients from five medical centers. Thirty-day readmission or mortality were ascertained using Medicare, state all-payer claims, and the National Death Index. We tested and externally validated the clinical models and the biomarker panels using area under the receiver-operating characteristics (AUROC) statistics. RESULTS: There were 112 patients (10.7%) who were readmitted or died within 30 days after coronary artery bypass graft surgery. The Society of Thoracic Surgeons augmented clinical model resulted in an AUROC of 0.66 (95% confidence interval: 0.61 to 0.71). The biomarker panel with The Society of Thoracic Surgeons augmented clinical model resulted in an AUROC of 0.74 (bootstrapped 95% confidence interval: 0.69 to 0.79, p < 0.0001). External validation of the model showed limited improvement with the addition of a biomarker panel, with an AUROC of 0.51 (95% confidence interval: 0.45 to 0.56). CONCLUSIONS: Although biomarkers significantly improved prediction of 30-day readmission or mortality in our derivation cohort, the external validation of the biomarker panel was poor. Biomarkers perform poorly, much like other efforts to improve prediction of readmission, suggesting there are many other factors yet to be explored to improve prediction of readmission.
引用
- Brown JR, Jacobs JP, Alam SS, et al. Utility of Biomarkers to Improve Prediction of Readmission or Mortality After Cardiac Surgery. Ann Thorac Surg. 2018. PMID: 30086283. doi:10.1016/j.athoracsur.2018.06.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。